Laboratory assessment of HDL heterogeneity and function;Evaluation au laboratoire de l'hétérogéné ité et des fonctions des HDL (version française)

Annales de Biologie Clinique

Volumn 67, Issue 1, 2009, Pages 7-21

  Movva, R ^a   Rader, D J ^a   Beaudeux, J L ^a  

^a NONE

Author keywords

Cardiovascular risk; Cholesterol; Function; HDL; Heterogeneity; Measurement; Subfraction

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

BLOOD; CARDIOVASCULAR DISEASE; HUMAN; PREDICTION AND FORECASTING; REVIEW; RISK FACTOR;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; LIPOPROTEINS, HDL; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 60349094790     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: 10.1684/abc.2008.0284     Document Type: Review

References (122)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update : a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006 ; 113 : e85-e151.
2. Gordon DJ, Rifkind BM. High-density lipoproteins-the clinical implications of recent studies. N Engl J Med 1989 ; 321 : 1311-6.
3. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988 ; 8 : 737-41.
4. Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001 ; 285 : 2486-97.
5. Alsheikh-Ali AA, Lin JL, Abourjaily P, et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007 ; 100 : 1499-501.
6. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and CV events. N Engl J Med 2007 ; 357 : 1301-10.
7. Kuivenhoven JA, Pritchard H, Hill J, et al. The molecular pathology of lecithin : cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997 ; 38 : 191-205 [Review] [102 refs].
8. Franceschini G, Sirtori CR, Capurso A, et al. A-IMilano apoprotein : decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980 ; 66 : 892-900.
9. Bruckert E, von Eckardstein A, Funke H, et al. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano. Atherosclerosis 1997 ; 128 : 121-8.
10. Hobbs HH, Rader DJ. ABC1 : connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest 1999 ; 104 : 1015-7.
11. Rader DJ. Molecular regulation of HDL metabolism and function : implications for novel therapies. J Clin Invest 2006 ; 116 : 3090-100.
12. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988 ; 260 : 641-51.
13. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events : VA-HIT : a randomized controlled trial. JAMA 2001 ; 285 : 1585-91.
14. Goldenberg I, Goldbourt U, Boyko V, et al. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol 2006 ; 97 : 466-71.
15. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on CV events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 2005 ; 366 : 1849-61.
16. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975 ; 231 : 360-81.
17. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients : long-term benefit with niacin. J Am Coll Cardiol 1986 ; 8 : 1245-55.
18. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2 : a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 ; 110 : 3512-7.
19. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 ; 345 : 1583-92.
20. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007 ; 297 : 499-508.
21. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004 ; 350 : 1505-15.
22. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein : an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004 ; 24 : 490-7.
23. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 ; 357 : 2109-22.
24. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 ; 356 : 1304-16.
25. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 ; 356 : 1620-30.
26. Rader DJ. Illuminating HDL : is it still a viable therapeutic target ? N Engl J Med 2007 ; 357 : 2180-3.
27. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals : two double-blind, randomised placebocontrolled phase I studies. Lancet 2007 ; 370 : 1907-14.
28. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol : from ultracentrifugation to homogeneous assays. Clin Chem 2001 ; 47 : 1579-96.
29. Langlois MR, Blaton VH. Historical milestones in measurement of HDL-cholesterol : impact on clinical and laboratory practice. Clin Chim Acta 2006 ; 369 : 168-78.
30. Zannis VI, Chroni A, Krieger M. Role of apoA-1, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006 ; 84 : 276-94.
31. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic CV disease. Nat Rev Drug Discov 2005 ; 4 : 193-205.
32. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005 ; 96 : 1221-32.
33. Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005 ; 115 : 1333-42.
34. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004 ; 95 : 764-72.
35. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006 ; 98 : 1352-64.
36. Lindgren FT, Elliott HA, Gofman JW. The ultracentrifugal characterization and isolation of human blood lipids and lipoproteins, with applications to the study of atherosclerosis. J Phys Colloid Chem 1951 ; 55 : 80-93.
37. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955 ; 34 : 1345-53.
38. Kirstein P, Carlson K. Determination of the cholesterol content of high density lipoprotein subfractions HDL2 and HDL3, without contamination of Lp(a), in human plasma. Clin Chim Acta 1981 ; 113 : 123-34.
39. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2- precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982 ; 28 : 1379-88.
40. Gidez LI, Miller GJ, Burstein M, et al. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982 ; 23 : 1206-23.
41. Salonen JT, Salonen R, Seppanen K, et al. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991 ; 84 : 129-39.
42. Lamarche B, Moorjani S, Cantin B, et al. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men : prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997 ; 17 : 1098-105.
43. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991 ; 325 : 373-81.
44. Sweetnam PM, Bolton CH, Yarnell JW, et al. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men : the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1994 ; 90 : 769-74.
45. Yu S, Yarnell JW, Sweetnam P, et al. High density lipoprotein subfractions and the risk of coronary heart disease : 9-years follow-up in the Caerphilly Study. Atherosclerosis 2003 ; 166 : 331-8.
46. Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med 2006 ; 26 : 787-802.
47. Blanche PJ, Gong EL, Forte TM, et al. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981 ; 665 : 408-19.
48. Warnick GR, McNamara JR, Boggess CN, et al. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med 2006 ; 26 : 803-46.
49. Asztalos BF, Sloop CH, Wong L, et al. Two-dimensional electrophoresis of plasma lipoproteins : recognition of new apo A-Icontaining subpopulations. Biochim Biophys Acta 1993 ; 1169 : 291-300.
50. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003 ; 23 : 847-52.
51. Asztalos BF, Cupples LA, Demissie S, et al. Highdensity lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004 ; 24 : 2181-7.
52. Asztalos BF, Collins D, Cupples LA, et al. Value of highdensity lipoprotein (HDL) subpopulations in predicting recurrent CV events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005 ; 25 : 2185-91.
53. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006 ; 26 : 847-70.
54. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002 ; 90 : 89-94.
55. Otvos JD, Collins D, Freedman DS, et al. Lowdensity lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High- Density Lipoprotein Intervention Trial. Circulation 2006 ; 113 : 1556-63.
56. Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007 ; 192 : 211-7.
57. van der Steeg WA, Holme I, Boekholdt SM, et al. Highdensity lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I : significance for CV risk : the IDEAL and EPICNorfoIk studies. J Am Coll Cardiol 2008 ; 51 : 634-42.
58. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) : a prospective study. Lancet 2001 ; 358 : 2026-33.
59. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, et al. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 2007 ; 116 : 2029-35.
60. Warden CH, Hedrick CC, Qiao J-H, et al. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science (Wash DC) 1993 ; 261 : 469-72.
61. Fruchart JC, Ailhaud G. Apolipoprotein A-containing lipoprotein particles : physiological role, quantification, and clinical significance. Clin Chem 1992 ; 38 : 793-7.
62. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition : particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res 1982 ; 23 : 747-53.
63. James RW, Hochstrasser D, Tissot JD, et al. Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. J Lipid Res 1988 ; 29 : 1557-71.
64. Atmeh RF, Shepherd J, Packard CJ. Subpopulations of apolipoprotein A-I in human high-density lipoproteins : their metabolic properties and response to drug therapy. Biochim Biophys Acta 1983 ; 751 : 175-88.
65. Puchois P, Kandoussi A, Fievet P, et al. Apolipoprotein A-I containing lipoproteins in coro-nary artery disease. Atherosclerosis 1987 ; 68 : 35-40.
66. Genest Jr. JJ, Bard JM, Fruchart JC, et al. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 1991 ; 90 : 149-57.
67. Parra HJ, Arveiler D, Evans AE, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992 ; 12 : 701-7.
68. Buring JE, O'Connor GT, Goldhaber SZ, et al. Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992 ; 85 : 22-9.
69. Asztalos BF, Demissie S, Cupples LA, et al. LpA-I, LpA-I : A-II HDL and CHD-risk : the Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. Atherosclerosis 2006 ; 188 : 59-67.
70. Blankenhorn DH, Alaupovic P, Wickham E, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts : lipid and nonlipid factors. Circulation 1990 ; 81 : 470-6.
71. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 2007 ; 117 : 746-56.
72. Shiflett AM, Bishop JR, Pahwa A, et al. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem 2005 ; 280 : 32578-85.
73. Tall AR. Role of ABCA1 in cellular cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2003 ; 23 : 710-1.
74. Haghpassand M, Bourassa PA, Francone OL, et al. Monocyte/macrophage expression ofABCA1 has minimal contribution to plasma HDL levels. J Clin Invest 2001 ; 108 : 1315-20.
75. Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to highdensity lipoproteins. Proc Natl Acad Sci USA 2004 ; 101 : 9774-9.
76. Kennedy MA, Barrera GC, Nakamura K, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005 ; 1 : 121-31.
77. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007 ; 117 : 2216-24.
78. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007 ; 117 : 3900-8.
79. Jian B, de la Llera-Moya M, Ji Y, et al. Scavenger receptor class B type I as a mediator of cellular cholesterolefflux to lipoproteins and phospholipid acceptors. J Biol Chem 1998 ; 273 : 5599-606.
80. Repa JJ, Mangelsdorf DJ. The liver X receptor gene team : potential new players in atherosclerosis. Nat Med 2002 ; 8 : 1243-8.
81. Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006 ; 113 : 90-7.
82. Terasaka N, Hiroshima A, Koieyama T, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptordeficient mice. FEBS Lett 2003 ; 536 : 6-11.
83. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002 ; 99 : 7604-9.
84. Levin N, Bischoff ED, Daige CL, et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 2005 ; 25 : 135-42.
85. Rothblat GH, de la Llera-Moya M, Atger V, et al. Cell cholesterol efflux : integration of old and new observations provides new insights. J Lipid Res 1999 ; 40 : 781-96.
86. Chirinos JA, Zambrano JP, Chakko S, et al. Ability of serum to decrease cellular acylCoA : cholesterol acyl transferase activity predicts CV outcomes. Circulation 2005 ; 112 : 2446-53.
87. Matsuura F, Wang N, Chen W, et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1- dependent pathway. J Clin Invest 2006 ; 116 : 1435-42.
88. Rothblat GH, de la Llera-Moya M, Favari E, et al. Cellular cholesterol flux studies : methodological considerations. Atherosclerosis 2002 ; 163 : 1-8.
89. Mendez AJ. Cholesterol efflux mediated by apolipoproteins is an active cellular process distinct from efflux mediated by passive diffusion. J Lipid Res 1997 ; 38 : 1807-21.
90. Yancey PG, Kawashiri MA, Moore R, et al. In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J Lipid Res 2004 ; 45 : 337-46.
91. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein- mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004 ; 109 : 3215-20.
92. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces suscepti bility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007 ; 48 : 1263-72.
93. Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007 ; 27 : 1132-8.
94. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport : key to the regression of atherosclerosis ? Circulation 2006 ; 113 : 2548-55.
95. Glomset JA. The plasma lecithins : cholesterol acyltransferase reaction. J Lipid Res 1968 ; 9 : 155-67.
96. Hovingh GK, Hutten BA, Holleboom AG, et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005 ; 112 : 879-84.
97. Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003 ; 49 : 1873-80.
98. Dobiasova M, Adler L, Ohta T, et al. Effect of labeling of plasma lipoproteins with [(3)H]cholesterol on values of esterification rate of cholesterol in apolipoprotein B-depleted plasma. J Lipid Res 2000 ; 41 : 1356-7.
99. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004 ; 45 : 1594-607.
100. Zhuang Y, Wang J, Qiang H, et al. Cholesteryl ester transfer protein levels and gene deficiency in Chinese patients with cardio- cerebrovascular diseases. Chin Med J (Engl) 2002 ; 115 : 371-4.
101. Klerkx AH, de Grooth GJ, Zwinderman AH, et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004 ; 34 : 21-8.
102. de Grooth GJ, Smilde TJ, Van Wissen S, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004 ; 173 : 261-7.
103. Zeller M, Masson D, Farmer M, et al. High serum cholesteryl ester transfer rates and small highdensity lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007 ; 50 : 1948-55.
104. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women : the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)- Norfolk population study. Circulation 2004 ; 110 : 1418-23.
105. Goto A, Sasai K, Suzuki S, et al. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects : a study based on coronaryangiography. Atherosclerosis 2001 ; 159 : 153-63.
106. Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol : a population- based study. J Clin Endocrinol Metab 2006 ; 91 : 3382-8.
107. Marschang P, Sandhofer A, Ritsch A, et al. Plasma cholesteryl ester transfer protein concentrations predict CV events in patients with coronary artery disease treated with pravastatin. J Intern Med 2006 ; 260 : 151-9.
108. Hibino T, Sakuma N, Sato T. Higher level of plasma cholesteryl ester transfer activity from high-density lipoprotein to apo B-containing lipoproteins in subjects with angiographically detectable coronary artery disease. Clin Cardiol 1996 ; 19 : 483-6.
109. de Vries R, Perton FG, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer is a determinant of intimamedia thickness in type 2 diabetic and nondiabetic subjects : role of CETP and triglycerides. Diabetes 2005 ; 54 : 3554-9.
110. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions : a possible peroxidative role for paraoxonase. J Clin Invest 1998 ; 101 : 1581-90.
111. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease : are activity and concentration more important than genotype ? Arterioscler Thromb Vasc Biol 2001 ; 21 : 1451-7.
112. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983 ; 35 : 1126-38.
113. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000 ; 275 : 17527-35.
114. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002 ; 106 : 484-90.
115. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003 ; 107 : 2775-9.
116. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002 ; 106 : 1127-32.
117. Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001 ; 42 : 1308-17.
118. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006 ; 48 : 715-20.
119. Yuhanna IS, Zhu Y, Cox BE, et al. Highdensity lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001 ; 7 : 853-7.
120. Kuhn FE, Mohler ER, Satler LF, et al. Effects of high density lipoprotein on acetylcholine induced coronary vasoreactivity. Am J Cardiol 1991 ; 68 : 1425-30.
121. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins : from bench to bedside. Arterioscler Thromb Vasc Biol 2003 ; 23 : 1724-31.
122. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NOdependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004 ; 113 : 569-81.